What Does MacroGenics (MGNX) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
MacroGenics (MGNX) is a US clinical-stage biotech company developing novel cancer therapeutics based on its bispecific antibody platform. Pipeline clinical progress, partnerships with large pharma players such as Gilead, and the company's financing situation are the key variables driving its stock price and outlook.
Subscribe🏢 What kind of company is MacroGenics?
MacroGenics (MGNX) is a US-based clinical-stage biotech company. Leveraging its antibody engineering technology, it researches and develops immuno-oncology and targeted therapies for cancer patients, and has applied its proprietary antibody platform across multiple internal pipelines and external collaboration programs.
The company develops novel cancer therapeutics using its proprietary antibody platforms, including bispecific and trispecific antibodies and antibody-drug conjugates. Multiple candidates have advanced into early- and mid-stage clinical trials, and licensing and co-development deals with large pharmaceutical companies also form a key pillar of the business.
How does MacroGenics make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Partnership and Collaboration Revenue | Core | Licensing, milestone, and research revenue from pharmaceutical companies including Gilead |
| Clinical Pipeline | Key Growth Driver | Clinical progress of internally developed oncology candidates |
MacroGenics' revenue reflects a structure typical of clinical-stage biotechs, in which collaboration revenue and milestones from partnerships dominate over proprietary product sales. Given the nature of drug development, sizable R&D expenses are continuously invested, resulting in highly volatile margins, while co-development programs with Gilead and the achievement of clinical milestones in the internal pipeline directly affect revenue and cash flow.
📐 MacroGenics market cap and company size
The market capitalization is $254.8M and the company has 293 people employees.
It is a clinical-stage oncology drug developer with a relatively small market cap among global biotechs, with its proprietary antibody platform and partnership assets as the core value drivers. The stock carries a small market cap and tends to exhibit high volatility depending on clinical results and financing conditions. As a non-dividend-paying growth-oriented drug developer, capital is primarily reinvested into R&D.
📈 MacroGenics outlook and stock price trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeClinical progress of its bispecific antibody and antibody-drug conjugate pipelines represents the medium- to long-term core growth driver. Late-stage advancement of bispecific antibody candidates, early clinical data readouts from ADC programs, and the progression of co-development programs with Gilead could serve as near-term stock catalysts. However, risks of clinical failures or delays, regulatory clinical holds or reviews, and potential dilution from additional financing are also at play.
- Clinical progress of bispecific and trispecific antibody platform pipelines
- Milestones from partnerships with large pharma players such as Gilead
- Data generation from antibody-drug conjugate programs
⚔️ MacroGenics core strengths and risks
Its proprietary antibody engineering platform and partnerships with large pharmaceutical companies are strengths, while development risks and funding variables inherent to clinical-stage drug developers are the key risks.
💪 Core Strengths
⚠️ Core Risks
🔄 MacroGenics competitors and related (beneficiary) stocks
It is classified as a peer clinical-stage oncology antibody developer. Within the same biotech sector, ZYME, another developer of oncology antibody and immuno-oncology drugs, is grouped as a direct competitor, while related tickers include its co-development partner and large biopharma GILD, as well as the large oncology biotech REGN. GILD is a partner directly linked through its co-development program with MacroGenics.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 ZYME | Zymeworks BC Inc | $26.24 | -0.7% | $1.9B | - | 23.5 | -72.31% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | $143.72 | -0.8% | $178.2B | - | 15.1 | -20.57% | 2.26% |
| REGN | Regeneron Pharmaceuticals Inc | $781.49 | -1.5% | $80.5B | 19.3 | 2.5 | 14.04% | 0.5% |
✅ MacroGenics investor checklist
Key checkpoints to review when considering MacroGenics. Given the characteristics of a clinical-stage drug developer, pipeline clinical data, partnership milestone progress, and cash position and financing situation serve as the near- to mid-term key variables.
| Checkpoint | Items to Confirm | Current Status |
|---|---|---|
| 🔬 Pipeline Progress | Clinical stage advancement and data readout schedules for key candidates | Early- and mid-stage trials in progress |
| 🤝 Partnership Milestones | Progress and revenue contribution from collaboration programs with Gilead and others | Co-development in progress |
| 💵 Cash and Funding Situation | R&D cash burn pace and need for additional financing | Monitoring required |
Clinical failures and delays are the key risks, and with many early-stage candidates, stock price volatility is high depending on development outcomes. Regulatory clinical holds or reviews and potential dilution from additional financing are also near-term volatility factors.
MacroGenics is a clinical-stage oncology drug developer equipped with a proprietary antibody platform and large pharma partnerships. Pipeline clinical data and partnership progress are the key variables to watch, and given the high volatility, dollar-cost averaging and a long-term perspective are recommended.
Subscribe Today's 5 AI picks, all free